Valuation: ViroGates A/S

Market Cap 74.26M 11.13M 9.93M 9.16M 8.32M 15.62M 1.05B 15.86M 110M 43.48M 552M 41.76M 40.87M 1.75B P/E 2024
-4.92x
P/E 2025 -10.2x
Enterprise Value 52.58M 7.88M 7.03M 6.49M 5.89M 11.06M 746M 11.23M 78.16M 30.79M 391M 29.57M 28.94M 1.24B EV / Sales 2024
10.5x
EV / Sales 2025 11.6x
Free-Float
25.48%
Yield 2024 *
-
Yield 2025 -
Current month-8.05%
1 month-20.79%
3 months-16.23%
6 months-27.27%
Current year-40.52%
1 week 7.8
Extreme 7.8
8
1 month 7.6
Extreme 7.6
10.2
Current year 7.6
Extreme 7.6
14
1 year 7.6
Extreme 7.6
17.4
3 years 4.98
Extreme 4.98
31
5 years 4.98
Extreme 4.98
175
10 years 4.98
Extreme 4.98
252
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 63 31/12/2000
Chief Executive Officer 58 31/03/2011
Director of Finance/CFO 35 28/02/2023
Director TitleAgeSince
Chairman 65 31/01/2015
Chairman 64 30/04/2022
Director/Board Member 59 31/03/2022
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-38.22%-53.22% 11.13M
-4.10%-8.54%+40.05%+66.99% 63.29B
-0.41%+3.27%+10.46%+72.82% 54.89B
+0.74%+4.04%+12.18%+88.71% 53.28B
+0.61%+2.69%+27.75%+50.97% 45.81B
-1.08%+2.19%+21.92%+131.38% 43.46B
-3.39%-0.83%+254.27%+571.04% 40.23B
-1.67%+6.70%+14.42%+56.67% 33.45B
+2.47%-3.86%+30.54%+0.41% 23.7B
+1.30%+4.94%+38.23%+28.59% 23.76B
Average -0.56%+1.14%+41.16%+101.44% 38.19B
Weighted average by Cap. -0.96%+0.89%+47.99%+121.93%

Financials

2024 2025
Net sales 7.14M 1.07M 955K 881K 801K 1.5M 101M 1.53M 10.62M 4.18M 53.11M 4.02M 3.93M 168M 8.9M 1.33M 1.19M 1.1M 998K 1.87M 126M 1.9M 13.24M 5.21M 66.21M 5.01M 4.9M 210M
Net income -14.34M -2.15M -1.92M -1.77M -1.61M -3.02M -204M -3.06M -21.32M -8.4M -107M -8.07M -7.9M -338M -10.4M -1.56M -1.39M -1.28M -1.17M -2.19M -148M -2.22M -15.45M -6.09M -77.31M -5.85M -5.72M -245M
Net Debt -6.91M -1.04M -924K -852K -774K -1.45M -98.05M -1.48M -10.27M -4.04M -51.37M -3.89M -3.8M -163M -21.67M -3.25M -2.9M -2.67M -2.43M -4.56M -308M -4.63M -32.22M -12.69M -161M -12.19M -11.93M -511M
Projected Income Statement - Annual - ViroGates A/S
Logo ViroGates A/S
ViroGates A/S is a Denmark-based medical technology company. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.
Employees
7
Date Price Change Volume
20/10/26 DKK 8.000 0.00% 43
19/10/26 DKK 8.000 -3.03% 1,254
16/10/26 DKK 8.250 +3.12% 400
15/10/26 DKK 8.000 +4.58% 63
14/10/26 DKK 7.650 -2.55% 163

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - ViroGates A/S
  1. Stock Market
  2. Stocks
  3. VIRO Stock